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Objectives: It is hypothesized that immune factors influence addictive behaviors and 
contribute to relapse. The primary study objectives were to (1) compare neuropsychiatric 
symptoms across adults with active methamphetamine (MA) dependence, in early remis-
sion from MA dependence, and with no history of substance dependence, (2) determine 
whether active or recent MA dependence affects the expression of immune factors, and (3) 
evaluate the association between immune factor levels and neuropsychiatric symptoms.
Methods: A cross-sectional study was conducted using between group comparisons 
and regression analyses to investigate associations among variables. Eighty-four adults 
were recruited into control (CTL) (n = 31), MA-active (n = 17), or MA-remission (n = 36) 
groups. Participants completed self-report measures of anxiety, depression, and memory 
complaints and objective tests of attention and executive function. Blood samples were 
collected, and a panel of immune factors was measured using multiplex technology.
results: Relative to CTLs, MA-dependent adults evidenced greater anxiety and depres-
sion during active use (p < 0.001) and remission (p < 0.007), and more attention, memory, 
and executive problems during remission (p < 0.01) but not active dependence. Regression 
analyses identified 10 immune factors (putatively associated with cytokine–cytokine 
receptor interactions) associated with anxiety, depression, and memory problems.
conclusion: While psychiatric symptoms are present during active MA dependence 
and remission, at least some cognitive difficulties emerge only during remission. Altered 
expression of a network of immune factors contributes to neuropsychiatric symptom 
severity.
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inTrODUcTiOn
Methamphetamine (MA) addiction is a pressing health concern 
and is a substance use disorder that faces many treatment chal-
lenges, including, but not limited to, the lack of effective treatments 
and the high prevalence of co-occurring mental and physical 
health conditions associated with the addiction. According to the 
2012 National Survey on Drug Use and Health, approximately 1.2 
million people reported using MA in the past year, and 440,000 
reported using it in the past month (1). The costs associated with 
MA use are numerous, with contributions from crime/criminal 
justice, child endangerment, lost productivity, drug treatment, 
health care, MA production hazards, and premature death esti-
mated at more than $23.4 billion in 2005 (2).
Exposure to MA impacts a range of both peripheral and central 
immune functions, such as alterations in B- and T-cell expression 
and response (e.g., antibody production, proliferation), natural 
killer cell activation, macrophage function (e.g., phagocytosis), 
glial cell-mediated cytokine expression, and immune cell traf-
ficking – which likely contribute to the chronicity of the drug’s 
adverse and neurotoxic effects (3–23). Furthermore, MA use is 
associated with structural and functional changes to regions of 
the brain that regulate cognitive and psychiatric function and 
promote drug-seeking behaviors, making recovery from MA 
addiction very difficult (24–28). Approximately 40% of chronic 
MA users experience global neuropsychiatric difficulties (e.g., 
memory, attention, and executive functions) (26, 29, 30), and 
one-third to one-half or more of MA-dependent adults evidence 
psychiatric disorders (e.g., anxiety and depression) during remis-
sion (31–35). Neuropsychiatric impairments that persist follow-
ing abstinence are associated with poorer treatment outcomes, 
including increased relapse rates, lower treatment retention rates, 
and reduced daily functioning (36–38).
Research is beginning to link immune factor signaling with 
neural and behavioral aspects of addiction, such as impaired 
cognitive function (10), drug seeking behaviors, and resilience to 
relapse (39–42). The immune system modulates central nervous 
system functions through a variety of signaling mechanisms, 
both in the absence and in the presence of immunological chal-
lenges (43–46). Likewise, numerous studies have demonstrated 
that peripheral alterations in the expression and function of 
immune factors (e.g., pro- and anti-inflammatory cytokines and 
chemokines) are evident in patients diagnosed with a range of 
neuropsychiatric and mental health disorders, including depres-
sion (47, 48), anxiety (49, 50), chronic fatigue syndrome (51), 
cancer-related fatigue and cognitive impairment (52), pain disor-
ders (53–56), hepatitis C virus (HCV)-associated neuropsychiat-
ric impairment (57), age-related cognitive decline and dementia 
(58–60), and, more recently, substance use disorders (10, 61). 
Collectively, these studies highlight the impact that immune 
activation and immune factor dysregulation (both peripherally 
and centrally) can have on central nervous system function.
In a translational study, we previously reported that mice 
exposed with repeated doses of MA evidence significantly altered 
expression of brain and plasma immune factors, both immedi-
ately following drug exposure and after a remission period, 
and that altered expression of several plasma immune factors 
is significantly correlated with reduced cognitive function in 
humans during remission from MA dependence (10). However, 
this study was limited to a panel of nine immune factors, and it 
did not include active MA users who may demonstrate different 
neuropsychiatric and immune consequences than those in remis-
sion from MA dependence. Although research investigating 
pathophysiological mechanisms and treatment approaches for 
MA addiction has been expanding, few studies have examined 
the relationship between immune factor expression and the 
development of commonly occurring neuropsychiatric symp-
toms in adults with MA use disorders. The primary objectives 
of the present study, therefore, were to (1) compare levels of 
anxiety, depression, and cognitive difficulties across three study 
groups  –  adults with active MA dependence, adults in early 
remission from MA dependence, and adult controls (CTLs) with 
no history of drug or alcohol dependence, (2) determine whether 
active or recent MA dependence and other covariates [age, gen-
der, ethnicity, body mass index (BMI), nicotine use, or medical 
comorbidities] significantly influence the expression of a larger 
array of immune factors, and (3) evaluate the association between 
peripheral immune factor expression and anxiety, depression, 
and cognition in adults with and without MA dependence. The 
functional significance of the immune factors found to be predic-
tive of neuropsychiatric impairments in our regression models 
was assessed using bioinformatics pathway analysis.
MaTerials anD MeThODs
research Participants
Eighty-four research participants gave informed consent, met all 
eligibility criteria, and were enrolled in the study; 29 others gave 
informed consent but were not enrolled in the study because they 
did not meet all eligibility criteria (i.e., they were screen fails). 
Participants were recruited from Portland area addiction treat-
ment centers and the community through word of mouth and via 
study advertisements posted in clinics, websites, and newspapers. 
Participants were recruited into one of three groups: (1) CTL 
group (n =  31): adults with no lifetime history of dependence 
on any substance other than nicotine or caffeine; (2) MA-active 
(ACT) group (n = 17): adults actively using MA and currently 
meeting criteria for MA dependence; and (3) MA-remission 
(REM) group (n = 36): adults in remission from MA dependence 
≥1 and ≤12 months.
General exclusion criteria included history of a major medical 
illness or current use of medications that are likely to be associ-
ated with serious neurological or immune dysfunction [e.g., 
stroke, traumatic brain injury, human immunodeficiency virus 
(HIV) infection, HCV infection, primary psychotic disorder, 
immunosuppressants, antivirals, anti-tumor necrosis factor 
(TNF)-alpha agents]. Additional exclusion criteria for the non-
dependent CTL group included: (1) meets criteria for lifetime 
history of dependence on any substance (other than nicotine or 
caffeine dependence) based on diagnostic and statistical manual 
of mental disorders-fourth edition (DSM-IV) (62) and confirmed 
by the Mini-International Neuropsychiatric Interview (MINI) 
(63) and (2) on the day of the study visits, tests positive on a urine 
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drug analysis for any drug of abuse. Additional inclusion criteria 
for the MA-ACT group included: (1) meets DSM-IV (62) criteria 
for dependence on MA, confirmed by the MINI (63), (2) average 
MA use was ≥2 days/week for ≥1 year (average years of depend-
ence = 13.91, SD = 10.00), and (3) last use of MA was ≤2 weeks 
ago (average days since last use =  2.25  days, SD =  2.21  days, 
range =  1–8). Note that all individuals in the MA-ACT group 
completed a urine drug analysis, and most (58.8%) tested positive 
for MA. MA is generally detectable by urine drug analysis for 
approximately 3–5 days depending on a variety of individual fac-
tors such as the pH level of the urine. Thus, we included 7 partici-
pants (41.2% of the group) who tested negative for MA, reported 
having last used MA ≥ 3 days ago, and who otherwise met all 
criteria for the group and study. Although this is a limitation in 
that we could not verify MA use for those individuals, many indi-
viduals use MA only 2–3 days/week, so this procedure allowed us 
to include a sample that was generalizable to a broader range of 
use patterns. Additional inclusion criteria for the MA-REM group 
included: (1) meets DSM-IV (62) criteria for dependence on MA, 
confirmed by the MINI (63), (2) average MA use ≥2 days/week 
for ≥1 year (average years of dependence = 11.24, SD = 5.77), (3) 
last use of MA was ≥1 and ≤12 months ago (average days since 
last use = 108.82, SD = 73.82, range = 35–273), and (4) on the day 
of the study visit, does not test positive on a urine drug analysis 
for MA or any other drugs of abuse.
ethical approval
The protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki (6th revision, 2008) and was approved by 
the Institutional Review Boards at the Veterans Affairs Portland 
Health Care System and Oregon Health & Science University.
Procedures
Research participants were compensated with grocery store 
vouchers ($50) to complete the following study procedures: 
clinical interview, urine drug analysis, HCV and HIV antibody 
screening, blood sample collection for multiplex immune factor 
analysis as described in the sections below, questionnaires to 
assess severity of anxiety, depression and memory complaints, 
and objective cognitive measures to assess attention and execu-
tive function. Given the scope of the study, in order to facilitate 
rapid enrollment across the 14-month enrollment period, study 
visits were kept below 90 min; our questionnaire and cognitive 
assessment battery was limited to 15  min and, thus, did not 
include a comprehensive battery of objective cognitive tests. All 
procedures, including blood sample collection, were completed 
by certified phlebotomist/retired Licensed Practical Nurse (LPN) 
who was trained and supervised by a licensed psychologist and 
clinical neuropsychologist (Marilyn Huckans). To ensure accu-
racy, all measures were scored and then re-scored by separate 
study personnel, and all data were entered into a database initially 
and then double-checked by separate study personnel prior to 
analysis.
Questionnaires and Cognitive Assessment Measures
 1. General anxiety disorder-7 scale (GAD-7) (64), a well-
validated 7-item measure of anxiety.
 2. Patient health questionaire-9 (PHQ-9) (65), a well-validated 
9-item measure of depression severity.
 3. Prospective and retrospective memory questionnaire (PRMQ) 
(66), a well-validated 16-item measure of self-reported 
memory complaints.
 4. Digits forward, neuropsychological assessment battery (NAB) 
(67), well-validated and widely used objective performance 
measure of simple auditory attention span and tracking.
 5. Letter fluency, Delis–Kaplan executive functioning system 
(D-KEFS) (68), a well-validated objective performance meas-
ure of verbal fluency and executive function.
Multiplex immune Factor assessments
Following all other study procedures, blood was drawn in the 
afternoon (mean time was 1:28 p.m., SD = 2:35 h) by one-time 
venipuncture into cell preparation tubes (BD Vacutainer Systems, 
Franklin Lakes, NJ, USA) containing 1 mL of 0.1M sodium citrate 
solution. The blood was then centrifuged at 1500 rpm for 20 min at 
room temperature (22–25°C). Plasma was separated, collected, and 
immediately aliquoted in polypropylene tubes (Phenix Research 
Products, Hayward, CA, USA) and frozen at −80°C until assayed. 
Samples were sent frozen in a single batch to Myriad Rules Based 
Medicine, Inc. (Austin, TX, USA) where they were thawed for 
assay without additional freeze–thaw cycles. Immune factors 
were measured using Myriad Rules Based Medicine, Inc.’s Human 
InflammationMAP v 1.0 panel, a biomarker panel designed to 
discern inflammatory patterns in biological samples including 
plasma. Myriad Rules Based Medicine, Inc. is a Clinical Laboratory 
Improvement Amendments (CLIA) certified laboratory. Assays 
conducted by this company utilizing this methodology have been 
published previously [e.g., Ref. (57, 69–71)]. This multiplex micro-
bead assay is based on Luminex technology (72) and measures 
proteins in a similar manner to standard sandwich enzyme-linked 
immunosorbent assays (ELISAs), with comparable sensitivity and 
range. Multiplex assays have been compared to regular high sensi-
tivity ELISAs in studies of Alzheimer’s disease, Parkinson’s disease, 
parasite infection, HIV, and others (73–76). Twenty-one factors from 
the original panel of 47 factors were undetectable (not measurable 
on the standard curve) in more than one-third of the total sample 
and were excluded from analyses [i.e., granulocyte-macrophage 
colony-stimulating factor, interferon-gamma, interleukin (IL)-
1alpha, IL-1beta, IL-1 receptor antagonist, IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-7, IL-10, IL-12p40, IL-12p70, IL-15, IL-17, macrophage 
inflammatory protein-1 alpha, matrix metalloproteinase-9, tumor 
necrosis factor (TNF)-alpha, and TNF-beta]. Table 2 summarizes 
the 26 remaining immune factors used for our analyses, including 
the factor’s abbreviation, unit of measurement, and the percentage 
within the total sample with detectable levels.
Bioinformatics Pathway analysis
Functional analysis of the immune factor expression data 
was performed using the DAVID (Database for Annotation, 
Visualization and Integrated Discovery v6.7) Bioinformatics 
Resources,1 as previously described, with minor modifications 
1 https://david.ncifcrf.gov/home.jsp
TaBle 1 | Between group comparisons of demographics, clinical characteristics, anxiety, depression, and cognition in adults with and without 
methamphetamine dependence.
cTl Ma-acT Ma-reM Ominbus model significant comparisons
Demographics
Age, mean years (SD)a 37.55 (13.84) 41.24 
(10.29)
36.78 (9.46) p = 0.393 n.s.
Male genderb 68% 81% 78% p = 0.515 n.s.
Caucasianb 81% 76% 81% p = 0.933 n.s.
Years of education, mean (SD)a 14.13 (1.41) 12.76 
(0.56)
12.08 (1.56) F (9, 74) = 3.45; p = 0.001** MA-ACT < CTL p = 0.006**
MA-REM < CTL p < 0.001***
clinical characteristics
Body mass index, mean (SD)a 29.00 (5.83) 28.27 
(6.01)
28.92 (5.54) p = 0.951 n.s.
Current tobacco useb 58% 94% 89% LR X2 = 12.40; p = 0.002** MA-ACT > CTL p = 0.011*
MA-REM > CTL p = 0.007**
Current prescription medication usec 32% 18% 51% – MA-REM > MA-ACT z = 2.39 p < 0.02*
Past medical diagnoses (any)b 52% 47% 58% p = 0.717 n.s.
Past psychiatric diagnosis (any)b,d 45% 41% 61% p = 0.277 n.s.
neuropsychiatric symptom severity
Anxiety (GAD-7), mean total score (SD)e 2.42 (3.21) 8.42 
(6.62)
5.44 (5.21) LR X2 = 12.16; p < 0.002*** MA-ACT > CTL z = 3.49 p < 0.001***
MA-REM > CTL z = 2.72 p < 0.001***
Depression (PHQ-9), mean total score (SD)e 2.61 (3.14) 8.41 
(6.39)
5.47 (5.43) LR X2 = 12.56; p < 0.002** MA-ACT > CTL z = 3.56 p < 0.001***
MA-REM > CTL z = 2.69 p < 0.007**
Memory complaints (PRMQ), mean total 
score (SD)e
28.84 (7.59) 34.47 
(6.55)
37.11 (11.71) F = 6.51; p = 0.002** MA-REM > CTL z = 3.58 p < 0.001***
Attention (NAB digits forward), mean z 
score (SD)a
0.31 (1.05) −0.007 
(0.98)
−0.33 (1.05) F = 3.37; p = 0.039* MA-REM < CTL z = −2.59 p < 0.001***
Executive function/verbal fluency (D-KEFS), 
mean z score (SD)a
0.46 (0.85) 0.10 
(1.06)
−0.92 (0.74) F = 3.54; p = 0.034* MA-REM < CTLS z = −2.64 p = 0.010**
aFor continuous variables with normal distributions, results reflect linear regressions with two dummy codes to reflect the membership across the three groups and test the group 
differences between the two drug conditions compared to controls. The p values reflect each dummy code testing two null hypotheses: MA-ACT = CTLs and MA-REM = CTLs.
bFor binary variables, p values reflect the results of logistic regressions with two dummy codes to test two null hypotheses: MA-ACT = CTLs and MA-REM = CTLs.
cMedication use was compared between groups with tests of proportions.
dPsychiatric diagnoses were based on diagnostic and statistical manual of mental disorders-fourth edition (DSM-IV) criteria verified using the Mini-International Neuropsychiatric 
Interview (MINI).
eFor non-normal distributions, p values reflect results from negative binomial regressions with two dummy codes for group membership. The p values reflect each dummy code 
testing two null hypotheses: MA-ACT = CTLs and MA-REM = CTLs.
CTL, adults with no history of drug or alcohol dependence based on DSM-IV criteria verified with the MINI; D-KEFS, Delis–Kaplan executive function system; GAD-7, generalized 
anxiety disorder 7-item scale; MA-ACT, adults meeting DSM-IV criteria for active methamphetamine dependence, verified with the MINI; MA-REM, adults meeting DSM-IV criteria 
for remission from methamphetamine dependence, verified with the MINI; NAB, neuropsychological assessment battery; n.s., non-significant (p > 0.050); PHQ-9, patient health 
questionnaire; PRMQ, prospective and retrospective memory questionnaire; PTSD, posttraumatic stress disorder.
*p ≤ 0.050.
**p ≤ 0.010.
***p ≤ 0.001.
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(71). Briefly, the 10 immune factors identified as significant 
predictors of neuropsychiatric symptoms (Table 3) were assessed 
for significant enrichment of biological processes using the terms 
of the fifth level of gene ontology (GO). The name of each factor 
was converted to an analyzable identifier via Universal Protein 
Resource (UniProt) and then entered in the DAVID functional 
annotation tool. Pathway mapping analysis was carried out using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) module 
within DAVID.
statistical analysis
Data analyses were conducted using Stata v.12 (StataCorp LP, 
College Station, TX, USA), with specific methodologies described 
in the footnotes for Tables 1–3. Significant p values were ≤0.050.
resUlTs
Demographics and clinical Data
Table  1 summarizes demographic data, clinical characteristics, 
MA use characteristics, and neuropsychiatric outcomes by study 
group. Groups differed significantly by education (on average 
CTLs had two more years of education than the MA groups), 
tobacco use (a lower proportion of CTLs used tobacco), and 
current medications (the MA-ACT group was significantly less 
likely to be taking any medications than the MA-REM group, but 
there were no significant differences between MA-ACT and CLTs 
or MA-REM and CTLs). There were no significant group differ-
ences in terms of age, gender, race, BMI, or rates of medical or 
psychiatric diagnoses; adults with severe or unstable medical or 
TaBle 2 | covariate analysis of plasma immune factor levels in adults with and without methamphetamine dependence.
immune factor (abbreviation) Units Total sample % with 
detectable factorsa (%)
cTls mean; 
median; sDb
Ma-acT mean; 
median; sDb
Ma-reM mean; 
median; sDb
Omnibus  
modelc
significant variabled
Alpha-2-macroglobulin (A2Macro) mg/mL 100 0.98; 1.00; 0.27 0.91; 0.86; 0.41 0.97; 0.95; 0.21 F (8, 74) = 4.46; p = 0.001*** MA-ACT (t = −2.39; p = 0.019)*
Age (t = −2.63; p = 0.010)*
Male (t = −3.19; p = 0.002)*
Alpha-1-antitrypsin (AAT) mg/mL 100 0.95; 0.94; 0.23 1.05; 1.10; 0.18 1.01; 0.97; 0.38 F (8, 74) = 0.80; p > 0.050
Beta-2-microglobulin (B2M) μg/mL 100 0.82; 0.80; 0.24 1.07; 1.00; 0.35 1.00; 0.87; 0.47 F (8, 74) = 2.34; p = 0.027* MA-REM (t = 2.00; p = 0.050)*
Caucasian (t = −2.21; p = 0.030)*
Brain-derived neurotrophic factor 
(BDNF)
ng/mL 100 1.91; 1.70; 0.80 2.36; 2.20; 1.17 2.52; 2.20; 1.30 F (8, 74) = 1.39; p > 0.050
C-reactive protein (CRP) μg/mL 100 2.87; 1.30; 3.42 1.46; 0.91; 1.70 2.13; 0.75; 3.18 F (8, 74) = 3.74; p = 0.001** BMI (t = 4.75; p < 0.000)***
Complement C3 (C3) mg/mL 100 0.65; 0.62; 0.16 0.64; 0.60; 0.13 0.70; 0.62; 0.41 F (8, 74) = 0.71; p > 0.050
Eotaxin-1 pg/mL 95 210.81; 200.00; 
73.38
242.42; 207.00; 
96.92
274.08; 243.30; 
116.13
F (8, 74) = 3.83; p = 0.001*** MA-REM (t = 2.30; p = 0.024)*
Caucasian (t = 2.44; p = 0.017)*
BMI (t = −3.10; p = 0.003)**
Factor VII ng/mL 100 331.23; 323.00; 
84.27
358.41; 370.00; 
80.32
310.11; 289.50; 
99.03
F (8, 74) = 3.39; p = 0.002** Age (t = 2.70; p = 0.009)**
Male (t = −3.65; p < 0.000)***
Ferritin ng/mL 100 61.17; 41.00; 
57.60
88.96; 64.00; 
72.28
68.50; 53.50; 63.80 F (8, 74) = 3.71; p = 0.001* Male (t = 3.70; p < 0.001)***
Caucasian (t = −2.55; p = 0.013)*
Fibrinogen mg/mL 100 2.34; 2.20; 0.61 2.25; 2.20; 0.50 2.41; 2.25; 0.92 F (8, 74) = 1.82; p > 0.050
Haptoglobin mg/mL 95 0.85; 0.77; 0.36 1.16; 1.00; 0.50 0.90; 0.81; 0.48 F (8, 74) = 1.72; p > 0.050
Intercellular adhesion molecule 1 
(ICAM-1)
ng/mL 100 79.71; 75.00; 
23.48
78.24; 77.00; 
25.09
79.53; 78.50; 18.58 F (8, 74) = 1.19; p > 0.050
Interleukin-8 (IL-8) pg/mL 77 4.67; 4.30; 3.55 3.98; 4.50; 2.41 3.85; 3.90; 3.20 F (8, 74) = 3.74; p = 0.001** BMI (t = 2.11; p = 0.038)**
Age (t = 3.80; p < 0.000)***
Interleukin-18 (IL-18) pg/mL 100 135.68; 133.00; 
64.48
118.94; 111.00; 
56.54
131.92; 140.00; 
44.51
F (8, 74) = 1.33; p > 0.050
Interleukin-23 (IL-23) ng/mL 79 0.40; 0.46; 0.24 0.53; 0.53; 0.16 0.35; 0.42; 0.30 F (8, 74) = 2.35; p = 0.026* Male (t = −2.47; p = 0.016)*
Caucasian (t = −2.06; p = 0.043)*
Age (t = 2.07; p = 0.042)*
Macrophage inflammatory protein-1 
beta (MIP-1 beta)
pg/mL 99 83.58; 79.00; 
37.60
70.36; 64.00; 
30.38
78.94; 70.50; 66.94 F (8, 74) = 1.19; p > 0.050
Matrix metalloproteinase-3 (MMP-3) ng/mL 100 6.17; 4.90; 2.73 9.39; 8.40; 4.57 7.83; 6.35; 5.66 F (8, 74) = 2.65; p = 0.013* Male (t = 3.19; p = 0.002)**
Monocyte chemotactic protein 1 
(MCP-1)
pg/mL 100 182.48; 172.00; 
55.42
190.47; 200.00; 
57.38
203.08; 186.50; 
81.64
F (8, 74) = 0.47; p > 0.050
Regulated on activation, normal T cell 
expressed and secreted (RANTES)
ng/mL 100 6.78; 6.80; 2.82 8.32; 7.50; 3.73 8.15; 7.25; 3.71 F (8, 74) = 1.66; p > 0.050
Stem cell factor (SCF) pg/mL 99 158.52; 157.00; 
45.56
178.29; 182.00; 
39.93
169.00; 163.50; 
78.58
F (8, 74) = 1.28; p > 0.050
Tissue inhibitor of metalloproteinases 
1 (TIMP-1)
ng/mL 100 38.58; 37.00; 7.96 42.65; 43.00; 5.51 41.11; 41.00; 7.97 F (8, 74) = 1.37; p > 0.050
Tumor necrosis factor receptor 2 
(TNFR2)
ng/mL 100 2.49; 2.40; 0.85 2.71; 2.80; 0.86 2.84; 2.40; 1.30 F (8, 74) = 0.87; p > 0.050
(Continued)
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psychiatric disorders were excluded from the study. MA-ACT and 
MA-REM groups reported significantly higher levels of anxiety 
and depression than CTLs. Relative to CTLs, the MA-REM group, 
but not the MA-ACT group, reported more memory problems 
and performed worse on tests of attention and executive function.
covariate analyses of Plasma immune 
Markers
Table 2 summarizes the results of regression analyses to deter-
mine if study group or covariates (age, race, gender, BMI, tobacco 
use, and any medical condition) significantly predicted each of 
the peripheral immune factor levels in the total sample. Each 
of the regression models had a single Type I error rate for the 
predictors (p < 0.05) that was determined by the omnibus test 
of the model fit, limiting the risk of Type I error due to multiple 
comparisons. Being in the MA-ACT group versus CTL group was 
significantly associated with lower levels of A2Macro, and being 
in the MA-REM group versus the CTL group was significantly 
associated with higher levels of B2M and eotaxin-1. Older age was 
significantly associated with lower levels of A2Macro and higher 
levels of factor VII, IL-23, and IL-8. Male gender was significantly 
associated with lower levels of A2Macro, factor VII, and IL-23, 
and higher levels of ferritin and MMP-3. Caucasian race was sig-
nificantly associated with lower levels of B2M, ferritin, and IL-23, 
and higher levels of eotaxin-1. BMI was significantly associated 
with higher levels of CRP, IL-8, and vWF, and lower levels of 
eotaxin-1. Neither using tobacco nor having a medical condition 
was significantly associated with any immune factor level.
immune Factor Predictors of anxiety, 
Depression, and cognition
As summarized in Table  3, across all participants, regressions 
(controlling for study group and age, race, gender, BMI, tobacco 
use, and any medical condition as covariates) revealed a direct 
relationship between plasma immune factor levels and anxiety, 
depression, and memory complaints; the overall regression 
models were not significant for attention or executive function 
and so were not included in the table. Each of the regression 
models had a single Type I error rate for the predictors that was 
determined by the omnibus test of the model fit, limiting the risk 
of Type I error due to multiple comparisons. Figure 1 summa-
rizes results from the regression models and shows the immune 
factors that were found to be significantly associated with each 
neuropsychiatric outcome. A total of 10 variables were found to 
be significantly associated with neuropsychiatric outcomes (i.e., 
CRP, eotaxin-1, fibrinogen, haptoglobin, ICAM-1, IL-8, IL-23, 
MMP-3, SCF, and VEGF).
Bioinformatic Functional analysis
Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways analysis feature of the database for annotation, 
visualization, and integrated discovery (DAVID), we analyzed 
the 10 immune factors found to be significantly associated with 
neuropsychiatric symptoms in Table 3 for significant interaction 
within biologically relevant pathways. In doing so, the cytokine–
cytokine receptor interaction pathway was determined to be most 
TaBle 3 | Multi-analyte regression modelsa.
anxiety Depression Memory complaints
Model fit lr X2 = 68.29; p = 0.0004 lr X2 = 80.29; p < 0.0001 F (34, 48) = 2.41; p = 0.0026
Variable b z p b z p b t p
Intercept 1.07 0.63 0.527 0.073 0.06 0.954 32.97 2.27 0.027*
MA-ACT 1.50 3.28 0.001** 1.04 3.24 0.001*** 5.75 1.52 0.135
MA-REM −0.52 1.43 0.153 0.45 1.67 0.095 9.85 3.23 0.002**
Age −0.022 −1.58 0.115 −0.0049 −0.54 0.588 −1.37 −1.23 0.223
Caucasian −0.059 −0.13 0.894 −0.073 −0.24 0.813 5.27 1.51 0.138
Male −0.27 −0.62 0.536 −0.702 −2.25 0.024* −0.045 −0.01 0.991
BMI −0.37 −1.41 0.158 0.033 1.69 0.091 0.012 0.05 0.958
Nicotine 0.45 1.14 0.254 0.34 1.16 0.247 2.74 0.82 0.419
Past medical 
diagnosis
−0.079 −0.32 0.752 0.16 0.86 0.388 0.64 0.30 0.767
AAT 0.46 0.59 0.553 −0.12 −0.22 0.828 −12.31 −1.84 0.072
A2Macro 0.22 0.33 0.744 0.60 1.22 0.224 −2.51 −0.44 0.660
B2M −0.46 −0.84 0.401 −0.44 −1.12 0.265 −3.10 −0.67 0.507
BDNF −0.0062 0.04 0.965 −0.09 0.92 0.356 −1.99 −1.47 0.147
CRP 0.16 2.46 0.014* 0.027 0.63 0.529 −1.00 −2.08 0.043*
C3 −1.39 −0.86 0.392 −0.0097 −0.01 0.993 −11.04 −1.04 0.302
Eotaxin-1 −0.0039 −2.28 0.022* −0.003 −2.42 0.015* −0.039 −3.14 0.003**
Factor VII −0.00084 0.46 0.648 −0.015 −1.13 0.260 0.011 0.68 0.499
Ferritin −0.0041 −1.65 0.099 −0.00015 0.09 0.932 −0.18 −0.87 0.390
Fibrinogen −0.57 −0.13 0.899 −0.69 −2.18 0.029* −1.50 −0.41 0.681
Haptoglobin 0.32 0.85 0.397 1.04 3.93 <0.001*** 3.77 1.17 0.249
ICAM-1 −0.014 −1.96 0.051 −0.015 −2.80 0.005** −0.022 −0.35 0.729
IL-8 0.14 −2.45 0.014* 0.12 2.94 0.003** 0.14 0.32 0.747
IL-18 0.0044 1.83 0.067 0.0018 1.00 0.316 0.021 0.94 0.352
IL-23 −2.03 −3.27 0.001*** −1.023 2.28 0.023* −1.28 −0.24 0.812
MIP-1 beta 0.00094 0.34 0.732 0.0016 0.89 0.373 0.007 0.33 0.745
MMP3 0.11 2.92 0.004** 0.071 2.66 0.008** 0.49 1.51 0.139
MCP1 −0.002 −1.27 0.204 −0.0017 −1.13 0.259 0.015 0.98 0.333
SCF 0.013 4.03 <0.001*** 0.0096 4.26 <0.001*** 0.014 0.53 0.598
RANTES 0.045 0.89 0.376 0.045 1.27 0.204 0.31 0.67 0.506
TIMP1 −0.026 −0.95 0.345 0.0088 0.41 0.683 0.27 1.10 0.277
TNFR2 −0.31 −1.36 0.173 −0.077 −0.46 0.648 0.23 0.12 0.906
VCAM1 0.0032 1.02 0.307 0.0008 0.34 0.734 −0.025 −1.00 0.324
VEGF 0.015 2.36 0.018* 0.0058 1.34 0.182 0.045 0.78 0.439
VDBP 0.001 0.40 0.690 0.00084 0.51 0.613 0.017 0.85 0.402
VWF −0.019 −1.50 0.134 −0.013 −1.41 0.159 0.052 0.52 0.604
aRegression models were developed in order to determine whether the panel of plasma immune markers was significantly predictive of each of the five neuropsychiatric outcome 
variables (i.e., anxiety, depression, memory complaints, attention, and executive function) within the total sample. For each neuropsychiatric outcome variable, regressions were 
estimated by a Maximum Likelihood function with assumptions of normal or negative binomial distributions depending on the shape of the outcome variable. Normal distributions 
were assumed for the attention, memory and executive function outcomes, and negative binomial distributions were assumed for the anxiety and depression variables. Models were 
calculated (shown in the table above) by simultaneously regressing the set of covariates and immune factors on each outcome variable. For each of the final regression models, 
fit parameters are presented as well as the unstandardized regression weights (b), z, or t values (depending on type of regression used) and p values for each immune marker. 
Positive b weights for the immune marker meant that scores on the neuropsychiatric outcome variable increased with the increase in the immune marker; those with negative values 
decreased when the neuropsychiatric variable increased. Results are not shown for the attention or executive function models because the overall models were not significant 
(p > 0.050). See Table 2 for immune factor abbreviations.
*p ≤ 0.050.
**p ≤ 0.010.
***p ≤ 0.001.
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relevant (p =  0.0002), incorporating five (i.e., eotaxin-1, IL-8, 
IL-23, SCF, and VEGF) of the previously identified 10 immune 
factors (Figure S1 in Supplementary Material; Table  4). Four 
other pathways – bladder cancer (p = 0.056), pathways in cancer 
(p = 0.07), NOD-like receptor signaling pathway (p = 0.082), and 
complement and coagulation (p = 0.091) – were also generated by 
the database; however, they did not reach statistical significance.
DiscUssiOn
This cross-sectional analysis of adults with and without a history 
of MA dependence indicates that, compared with non-dependent 
CTLs, both active MA users and those in recent remission from 
MA dependence report significantly (p <  0.050) higher levels 
of anxiety and depression (Table  1). Notably, while adults in 
FigUre 1 | immune factors predict self-reported anxiety, depression, 
and memory problems. Two to eight immune factors were significant 
predictors of neuropsychiatric function within each of the regression models, 
for a total of 10 significant immune factors across all models.
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remission from MA dependence reported significantly more 
memory problems and performed worse on attention and execu-
tive function tasks than CTLs, active MA users did not evidence 
these cognitive deficits relative to CTLs (Table 1). While numer-
ous studies have documented cognitive impairments in adults in 
remission from MA dependence (10, 26, 29, 30), relatively few 
have examined cognitive function in non-intoxicated adults dur-
ing active dependence (i.e., non-remission). Our findings suggest 
that pathological processes that occur following abstinence from 
MA dependence, rather than during active use per se, result in 
at least some cognitive problems that initially appear and persist 
during remission.
Results additionally suggest that current and recent MA 
dependence, age, gender, race, and BMI can significantly impact 
peripheral immune signaling, as they were each significant pre-
dictors of some but not all plasma immune factor levels in our 
sample (Table 2). This is consistent with the previous literature 
showing altered peripheral immune signaling in substance users 
(10, 61), older adults (59), women (77), black Americans (78), 
and adults with higher BMI (79).
Moreover, results show that differences in the expression of 
a network of peripheral immune proteins significantly impact 
neuropsychiatric function in adults both with and without pre-
sent or past MA dependence. In our regression models (which 
controlled for covariates that might impact neuropsychiatric 
function or immune factor expression  –  MA dependence, age, 
gender, race, BMI, nicotine use, and medical comorbidities), a 
subset of immune factors significantly predicted self-reported 
anxiety, depression, and memory problems (Table 3). Specifically, 
two to eight immune factors were significant predictors of neu-
ropsychiatric function within each of the regression models, for 
a total of 10 significant immune factors across all models – CRP, 
eotaxin-1, fibrinogen, haptoglobin, ICAM-1, IL-8, IL-23, MMP-
3, SCF, and VEGF (Figure 1).
A major goal of this study was to identify novel biomarkers that 
might be relevant to the treatment of neuropsychiatric symptoms, 
including the context of MA use disorder, and these 10 significant 
predictors are thus potentially worthy of further investigation 
through additional studies (e.g., as treatment targets). It is 
notable that each of these factors have both immunoregulatory 
and neuromodulatory functions (see Table 4 for a summary of 
their actions), with the potential to both enhance inflammatory 
responses and adversely impact neuronal functions (e.g., induce 
microstructural white matter damage, impair phagocytosis, alter 
cell trafficking, and compromise BBB integrity) when dysregu-
lated. Thus, our results suggest that efforts to develop and inves-
tigate novel immunotherapies as treatments for neuropsychiatric 
symptoms (particularly in the context of substance use disorders) 
are warranted.
In animal models of MA addiction and other substance use 
disorders, a variety of addictive behaviors (e.g., withdrawal, 
craving, conditioned place preference, locomotor sensitization, 
self-administration, sedation, and motor impairments) have been 
significantly altered through interventions that directly impact 
immune signaling (80, 81). Consequently, immunotherapies that 
are designed to simultaneously “normalize” immunoregulation 
and neuromodulation may be particularly effective in treating 
neuropsychiatric symptoms that can contribute to and exacer-
bate substance abuse. Clinical trials have already demonstrated 
the antidepressant benefits of several immunotherapies, such as 
etanercept (TNF-alpha antagonist used to treat a range of autoim-
mune conditions, including psoriasis and arthritis), infliximab 
(monoclonal antibody against TNF-alpha also used for the treat-
ment of autoimmune diseases), and celecoxib [cyclooxygenase 
(COX)-2 inhibitor used to treat pain and arthritis] (82, 83). 
Additional immunotherapies for the treatment of neuropsychiat-
ric and substance use disorders are currently under investigation 
by our lab and others. For example, our recent preclinical efficacy 
data demonstrate that RTL551, a partial major histocompat-
ibility construct (pMHC) and novel neuroimmune modulator, 
effectively reduces MA-induced memory deficits in mice (84) 
and regulates the expression of pro-inflammatory cytokines (84), 
indicating that the immune system modulates the pharmacody-
namics and behavioral consequences of drug actions. Similarly, 
ibudilast (AV-411 or MN-166), a less specific peripheral and 
central anti-inflammatory agent, reduces MA self-administration 
and stress-induced relapse in rodents (85–87) and is currently 
being evaluated as a potential neuroimmune therapy for adults 
with MA, opioid, or alcohol use disorders.2
The present study includes several limitations. A cross-
sectional study design does not allow for definitive conclusions 
on causality, and group sample sizes may have limited our sta-
tistical power. Regression analyses are considered exploratory 
in nature and should be interpreted cautiously prior to replica-
tion. Our sample was largely middle aged, male, and Caucasian, 
with all adults residing in one Northwest metropolitan area (the 
greater Portland area), so results may not be generalizable to 
more diverse populations. Our study was limited to a panel of 
peripheral plasma immune proteins; additional biomarkers 
and functional pathways of interest may be revealed by future 
human studies, including gene arrays, or through animal studies 
that are better able to evaluate brain tissue for central immune 
2 www.clinicaltrials.gov
TaBle 4 | immune and neuromodulatory effects of inflammatory factors associated with neuropsychiatric symptomatology.
Factora immune and neuromodulatory effects reference
CRP Protein produced by the liver and released into blood plasma in acute response to injury (and therefore inflammation). It 
serves to activate the complement system, promoting phagocytosis. Higher levels of CRP have been associated with a 
greater risk of dementia, microstructural white matter damage, and poorer scores on executive function tests, but there are 
also findings that lower levels of CRP and other mediators of inflammation are associated with moderate alcohol use
(90–93)
*Eotaxin-1 Small CC chemokine (a.k.a. CCL-11) involved in eosinophil chemotaxis. Studies in mice have related early exposure to 
eotaxin-1 to decreased cognitive performance and hippocampal neurogenesis. In humans, serum levels of eotaxin-1 are 
increased in schizophrenic and late-stage bipolar patients as compared to controls
(94–96)
Fibrinogen Large glycoprotein involved in the formation of blood clots. While normally blocked by the blood brain barrier (BBB), 
infiltration of fibrinogen into the brain, such as in the case of Alzheimer’s disease, has been linked with an exacerbation of 
vascular damage. Reduced levels of fibrinogen are associated with moderate alcohol consumption, as has been reported for 
other inflammatory biomarkers (e.g., CRP, ICAM-1)
(91, 92, 97, 98)
Haptoglobin Acute-phase reactant protein that binds free hemoglobin when it is released from erythrocytes. Elevated plasma haptoglobin 
levels are observed in an animal model of neuropsychiatric lupus (mice display increased depressive-like behaviors and 
memory deficits)
(99)
ICAM-1 Transmembrane protein present in leukocytes and endothelial cells, the concentration of which increases upon cytokine 
stimulation – for example, following inflammatory pain. In the case of acute inflammation-related pathology (i.e., ischemia, 
autoimmune disorders, and encephalitis) the rise in ICAM-1 strongly correlates with increased BBB permeability. Exposure 
to substances of abuse can result in differential effects on circulating levels of ICAM-1. For example, moderate alcohol 
consumption is associated with significantly lower serum ICAM-1 levels, as compared to both heavy alcohol consumption 
and no consumption (abstinence)
(100–103)
*IL-8 Macrophage-produced chemokine that attracts neutrophils, basophils, and T-cells. The use of MA has been shown to 
increase LPS-mediated IL-8 expression in human macrophages. In one study, CSF IL-8 expression post TBI was 1000 times 
higher than plasma IL-8 levels, suggesting that it plays a prominent role in modulating neuroinflammation
(104–107)
*IL-23 Heterodimeric cytokine is composed of an IL-23p40 subunit and an IL-23p19 subunit. A decline in serum IL-23 levels is 
observed in animal models of stress-induced depression, and the reduction in IL-23 is associated with a reduced proportion 
of T helper 17 cells with decreased proliferation capacity
(108)
MMP-3 Stromelysin endopetidase involved in extracellular matrix remodeling. High concentrations of MMP-3 are seen in the case of 
severe TBI, where the elevated MMP-3 is associated with inflammation, BBB disruption, bleeding, and cell death
(109–111)
*SCF Cytokine that plays a role in hematopoiesis, spermatogenesis, and melanogenes. SCF is overexpressed by neurons and glial 
following brain injury and has been shown to produce an angiogenic response in vivo in part by recruiting progenitor cells to 
damaged sites
(112, 113)
*VEGF Signaling protein and a subfamily of growth factors involved in vasculogenesis as well as angiogenesis. VEGF overexpression 
drives BBB leakage in the case of ischemia, and elevated serum levels of VEGF are observed in animal models of stress-
related brain disorders
(114–116)
aSee Table 2 for a list of immune factor abbreviations. Factors with an asterisk (*) were identified by the KEGG pathway analyses as having functional relevance within the cytokine–
cytokine receptor interaction pathway (Figure S1 in Supplementary Material).
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factor expression. Our study included only a brief battery of 
questionnaires and cognitive assessment measures. Although 
we did not find a significant relationship between our immune 
factors and our two objective cognitive measures (i.e., digit span 
and fluency), we did find a significant relationship between our 
immune factors and self-reported memory complaints. Future 
studies could, therefore, include a more comprehensive battery 
of objective cognitive tests to determine whether immune 
factors are more predictive of subjective cognitive complaints 
versus objective cognitive performance. Lastly, it should be 
noted that this study was exploratory in nature (i.e., included 
a large array of immune factors without a  priori hypotheses 
about each) and should be replicated before results are deemed 
definitive.
Despite limitations, our results demonstrate that, relative 
to non-dependent CTL participants, MA-dependent adults 
evidence anxiety and depressive symptoms both during active 
use and remission, and they experience difficulties with aspects 
of cognition (attention, memory, and executive function) that 
initially develop and then persist only during remission  –  an 
observation with noteworthy treatment implications (88). To the 
best of our knowledge, this is one of first studies to investigate 
the role of inflammatory immune factors on neuropsychiatric 
symptoms in adults with active MA dependence, as compared to 
both adults in remission from MA and to non-dependent CTLs. 
Results suggest that altered expression of a network of plasma 
immune factors contributes to neuropsychiatric symptom sever-
ity (i.e., anxiety, depression, and memory problems) in adults 
with and without MA addiction. Moreover, our study identified 
10 immune factors (CRP, eotaxin-1, fibrinogen, haptoglobin, 
ICAM-1, IL-8, IL-23, MMP-3, SCF, and VEGF) that may be 
particularly relevant to neuropsychiatric symptoms, given their 
putative roles in cytokine–cytokine receptor interactions (Figure 
S1 in Supplementary Material) and in the regulation of both 
immune and neuronal functions (Table 4). Thus, although the 
pathophysiological mechanisms contributing to MA addiction 
are not fully understood, immune dysregulation and immune 
factors, such as cytokines, chemokines, and cellular adhesion 
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molecules, likely play a critical role in perpetuating MA-induced 
neuronal injury and neuropsychiatric impairments (10, 89).
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